| Life Launch Counseling, Llc | |
|
3030 S 9th St Ste 3f Kalamazoo MI 49009-9456 | |
| (269) 743-6139 | |
| Not Available |
| Full Name | Life Launch Counseling, Llc |
|---|---|
| Speciality | Counselor |
| Location | 3030 S 9th St Ste 3f, Kalamazoo, Michigan |
| Authorized Official Name and Position | Maryann Rigoni-southland (DIRECTOR) |
| Authorized Official Contact | 2697436139 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Life Launch Counseling, Llc 3030 S 9th St Ste 3f Kalamazoo MI 49009-9456 Ph: (269) 743-6139 | Life Launch Counseling, Llc 3030 S 9th St Ste 3f Kalamazoo MI 49009-9456 Ph: (269) 743-6139 |
| NPI Number | 1073054359 |
|---|---|
| Provider Enumeration Date | 03/20/2017 |
| Last Update Date | 03/20/2017 |
| Medicare PECOS PAC ID | 3375970635 |
|---|---|
| Medicare Enrollment ID | O20200226000406 |
News Archive
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.
Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.
A new report from researchers at the Johns Hopkins Bloomberg School of Public Health offers recommendations aimed at federal, state, and local policymakers to address the opioid epidemic during the pandemic, which has seen sharp increases in fatal and nonfatal overdoses.
According to a recent study carried out in Denmark women who exercise intensively during the first phase of pregnancy are 3.7 times more likely to miscarry.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073054359 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | 6401008766 (Michigan) | Primary |
| 103TC1900X | Psychologist - Counseling | 6301011550 (Michigan) | Secondary |
| Provider Name | Carolyn K Daniels Krupp |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1467587857 PECOS PAC ID: 1557305729 Enrollment ID: I20050617000753 |
News Archive
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.
Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.
A new report from researchers at the Johns Hopkins Bloomberg School of Public Health offers recommendations aimed at federal, state, and local policymakers to address the opioid epidemic during the pandemic, which has seen sharp increases in fatal and nonfatal overdoses.
According to a recent study carried out in Denmark women who exercise intensively during the first phase of pregnancy are 3.7 times more likely to miscarry.
› Verified 8 days ago
| Provider Name | Maryann Rigoni-southland |
|---|---|
| Provider Type | Practitioner - Psychologist Billing Independently |
| Provider Identifiers | NPI Number: 1134109226 PECOS PAC ID: 1456572742 Enrollment ID: I20141031000151 |
News Archive
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.
Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.
A new report from researchers at the Johns Hopkins Bloomberg School of Public Health offers recommendations aimed at federal, state, and local policymakers to address the opioid epidemic during the pandemic, which has seen sharp increases in fatal and nonfatal overdoses.
According to a recent study carried out in Denmark women who exercise intensively during the first phase of pregnancy are 3.7 times more likely to miscarry.
› Verified 8 days ago
| Provider Name | Lesa M Brenner |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1871051698 PECOS PAC ID: 6406273465 Enrollment ID: I20200904001671 |
News Archive
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.
Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.
A new report from researchers at the Johns Hopkins Bloomberg School of Public Health offers recommendations aimed at federal, state, and local policymakers to address the opioid epidemic during the pandemic, which has seen sharp increases in fatal and nonfatal overdoses.
According to a recent study carried out in Denmark women who exercise intensively during the first phase of pregnancy are 3.7 times more likely to miscarry.
› Verified 8 days ago
| Provider Name | Amanda Freeman |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1194267807 PECOS PAC ID: 4183003387 Enrollment ID: I20220617001864 |
News Archive
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.
Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.
A new report from researchers at the Johns Hopkins Bloomberg School of Public Health offers recommendations aimed at federal, state, and local policymakers to address the opioid epidemic during the pandemic, which has seen sharp increases in fatal and nonfatal overdoses.
According to a recent study carried out in Denmark women who exercise intensively during the first phase of pregnancy are 3.7 times more likely to miscarry.
› Verified 8 days ago
News Archive
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.
Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.
A new report from researchers at the Johns Hopkins Bloomberg School of Public Health offers recommendations aimed at federal, state, and local policymakers to address the opioid epidemic during the pandemic, which has seen sharp increases in fatal and nonfatal overdoses.
According to a recent study carried out in Denmark women who exercise intensively during the first phase of pregnancy are 3.7 times more likely to miscarry.
› Verified 8 days ago
True2u Counseling Llp Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4000 Portage St Ste 111, Kalamazoo, MI 49001 Phone: 269-365-0128 | |
Dawn Wood Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3503 Greenleaf Blvd Ste 202, Kalamazoo, MI 49008 Phone: 269-808-0160 | |
David L. Thayer, Psy.d.,p.c. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 821 W South St, Suite D, Kalamazoo, MI 49007 Phone: 269-501-3493 Fax: 269-344-5973 | |
Barbara W. Gustin, Lmsw, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2001 Hudson Ave, Kalamazoo, MI 49008 Phone: 269-352-6644 | |
Jennifer Langeland Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 400 S Rose St Apt 401, Kalamazoo, MI 49007 Phone: 269-330-4695 | |
Rootead Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1501 Fulford St, Kalamazoo, MI 49001 Phone: 269-358-8670 | |
Restorative Solutions Counseling And Consulting Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2031 Rambling Rd Ste 1, Kalamazoo, MI 49008 Phone: 269-224-2791 |